Patent · US Active

Fused tricyclic compounds as mTOR inhibitors

US8901142B2 · kind B2 · utility

0Cited by

0References

13Claims

0Family size

Assignee

Merck Sharp & Dohme LLC · US

Inventors

Zhaoyang Meng · Ambler, US
M. Arshad Siddiqui · Newton, US
Panduranga Adulla P. Reddy · Walpole, US
Mehul Patel · Blue Bell, US
Yang Nan · Nanjing, CN

Key dates

Filing date	Jul 20, 2012
Grant date	Dec 2, 2014
Priority date	—
Expiry date	Jul 20, 2032

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D519/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to certain pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine and dipyrazolopyrimidine compounds of Formula (I) as inhibitors of mammalian Target Of Rapamycin (mTOR) kinase, which is also known as FRAP, RAFT, RAPT or SEP. The compounds may be used in the treatment of cancer and other disorders where mTOR is deregulated. The present invention further provides pharmaceutical compositions comprising the pyrazolo[1,5-a]pyrrolo[3,2-e]pyrimidine or dipyrazolopyrimidine compounds.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.